Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.

Komurcuoglu B, Cirak AK, Kirakli SC, Polat G, Yucel N, Usluer O, Erer O, Balci G, Gayaf M, Guldaval F, Aktogu S, Guclu S, Ozsoz A, Halilcolar H.

Tumori. 2014 Jan-Feb;100(1):55-9. doi: 10.1700/1430.15816.

PMID:
24675492
2.

Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.

Suzuki H, Asami K, Hirashima T, Okamoto N, Yamadori T, Tamiya M, Morishita N, Shiroyama T, Takeoka S, Osa A, Azuma Y, Okishio K, Kawaguchi T, Atagi S, Kawase I.

Lung. 2014 Feb;192(1):191-5. doi: 10.1007/s00408-013-9516-y. Epub 2013 Oct 20.

PMID:
24141556
3.

A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.

Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S, Yamazaki S, Hirabayashi M, Nakano T, Fukuhara S.

Jpn J Clin Oncol. 2015 Jun;45(6):562-8. doi: 10.1093/jjco/hyv039. Epub 2015 Apr 2.

4.

Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.

Berardi R, Fiordoliva I, De Lisa M, Ballatore Z, Caramanti M, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Onofri A, Cascinu S.

Tumori. 2016 Mar-Apr;102(2):190-5. doi: 10.5301/tj.5000418. Epub 2016 Feb 12.

PMID:
26893272
5.

Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.

Rena O, Boldorini R, Papalia E, Mezzapelle R, Baietto G, Roncon A, Casadio C.

Ann Thorac Surg. 2015 Apr;99(4):1177-83. doi: 10.1016/j.athoracsur.2014.11.050. Epub 2015 Feb 7.

PMID:
25669666
6.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.

Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.

PMID:
26538423
7.

The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.

Giroux Leprieur E, Hirata T, Mo M, Chen Z, Okamoto J, Clement G, Li H, Wislez M, Jablons DM, He B.

Lung Cancer. 2014 Sep;85(3):465-71. doi: 10.1016/j.lungcan.2014.06.018. Epub 2014 Jun 30.

PMID:
25023662
8.

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.

9.

Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.

Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, Chessa L, Nicolò G, Serra M, Capaccio A, et al.

Anticancer Res. 1993 May-Jun;13(3):683-9.

PMID:
8317897
10.

Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.

Kaya H, Sezgı C, Tanrıkulu AC, Taylan M, Abakay O, Sen HS, Abakay A, Kucukoner M, Kapan M.

Neoplasma. 2014;61(4):433-8. doi: 10.4149/neo_2014_053.

PMID:
24645844
11.

Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.

Kapeles M, Gensheimer MF, Mart DA, Sottero TL, Kusano AS, Truong A, Farjah F, Laramore GE, Stelzer KJ, Patel SA.

Am J Clin Oncol. 2018 Jan;41(1):30-35. doi: 10.1097/COC.0000000000000225.

PMID:
26353120
12.

Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.

Metintas M, Metintas S, Ucgun I, Gibbs AR, Harmanci E, Alatas F, Erginel S, Tel N, Pasaoglu O.

Respir Med. 2001 Oct;95(10):829-35.

13.

Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.

Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I.

J Thorac Cardiovasc Surg. 2015 Jun;149(6):1539-46.e1. doi: 10.1016/j.jtcvs.2015.01.065. Epub 2015 Feb 12.

14.

Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.

Ak G, Metintas S, Metintas M, Yildirim H, Erginel S, Kurt E, Alatas F, Cadirci O.

J Thorac Oncol. 2009 Nov;4(11):1425-30. doi: 10.1097/JTO.0b013e3181ba2033.

15.

Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.

Elkiran ET, Kaplan MA, Sevinc A, Aksoy S, Demirci U, Seker M, Harputluoglu H, Ozdemir NY, Isik F, Ulas A, Inanc M, Arslan UY, Dogu GG, Isikdogan A, Buyukberber S; Anatolian Society of Medical Oncology Group.

Med Oncol. 2012 Dec;29(5):3147-54. doi: 10.1007/s12032-012-0276-y. Epub 2012 Jun 22.

PMID:
22722923
16.

Prognostic factors and survival in malignant pleural mesothelioma.

Van Gelder T, Damhuis RA, Hoogsteden HC.

Eur Respir J. 1994 Jun;7(6):1035-8.

17.

Prognostic factors for 100 patients with malignant pleural mesothelioma.

Gonlugur U, Gonlugur TE.

Arch Environ Occup Health. 2010 Apr-Jun;65(2):65-9. doi: 10.1080/19338240903390271.

PMID:
20439224
18.

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG.

J Thorac Oncol. 2016 Feb;11(2):249-55. doi: 10.1016/j.jtho.2015.10.003. Epub 2015 Dec 10.

19.

Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.

Koyuncu A, Koksal D, Ozmen O, Demirag F, Bayiz H, Aydogdu K, Berkoglu M.

J Cancer Res Ther. 2015 Jan-Mar;11(1):216-22. doi: 10.4103/0973-1482.138094.

20.

Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.

Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW; IASLC Staging Committee and Participating Institutions.

J Thorac Oncol. 2014 Jun;9(6):856-64. doi: 10.1097/JTO.0000000000000181.

Supplemental Content

Support Center